A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.

NCT Number	NCT06820723
Lead Sponsor	Ohio State University
Conditions	Depression, Anxiety, Major Depressive Disorder
Enrollment	40 participants
Start Date	2026-08-01
Primary Completion	2028-09 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-23